|
|
 Previous Article | Table of Contents | Next Article 
Blood, Vol. 93 No. 12 (June 15), 1999:
pp. 4309-4317
Identification of HLA-A2-Restricted T-Cell Epitopes Derived From the
MUC1 Tumor Antigen for Broadly Applicable Vaccine Therapies
Peter Brossart,
Kathrin S. Heinrich,
Gernot Stuhler,
Lars Behnke,
Volker L. Reichardt,
Stefan Stevanovic,
Alexandra Muhm,
Hans-Georg Rammensee,
Lothar Kanz, and
Wolfram Brugger
From the Department of Hematology, Oncology and Immunology,
University of Tübingen, Tübingen, Germany; and the
Department of Immunology, Institute for Cell Biology, Tübingen,
Germany.
The tumor-associated antigen MUC1 is overexpressed on various
hematological and epithelial malignancies and is therefore a suitable
candidate for broadly applicable vaccine therapies. It was demonstrated
that major histocompatibility complex (MHC)-unrestricted cytotoxic T cells can recognize epitopes of the MUC1 protein core localized in the tandem repeat domain. There is increasing evidence now
that MHC-restricted T cells can also be induced after immunization with
the MUC1 protein or segments of the core tandem repeat. Using a
computer analysis of the MUC1 amino acid sequence, we identified two
novel peptides with a high binding probability to the HLA-A2 molecule.
One of the peptides is derived from the tandem repeat region and the
other is derived from the leader sequence of the MUC1 protein,
suggesting that, in contrast to previous reports, the MUC1-directed
immune responses are not limited to the extracellular tandem repeat
domain. Cytotoxic T cells (CTL) were generated from several healthy donors by primary in vitro immunization using peptide-pulsed dendritic cells. The addition of a Pan-HLA-DR binding peptide PADRE as a T-helper epitope during the in vitro priming resulted in an increased cytotoxic activity of the MUC1-specific CTL
and a higher production of cytokines such as interleukin-12 and
interferon- in the cell cultures, demonstrating the importance of
CD4 cells for an efficient CTL priming. The peptide induced CTL lysed
tumors endogenously expressing MUC1 in an antigen-specific and
HLA-A2-restricted fashion, including breast and pancreatic tumor cells
as well as renal cell carcinoma cells, showing that these peptides are
shared among many tumors. The use of MUC1-derived peptides could
provide a broadly applicable approach for the development of dendritic
cell-based vaccination therapies.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
C. Ding, L. Wang, J. Marroquin, and J. Yan
Targeting of antigens to B cells augments antigen-specific T-cell responses and breaks immune tolerance to tumor-associated antigen MUC1
Blood,
October 1, 2008;
112(7):
2817 - 2825.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Vasir, Z. Wu, K. Crawford, J. Rosenblatt, C. Zarwan, A. Bissonnette, D. Kufe, and D. Avigan
Fusions of Dendritic Cells with Breast Carcinoma Stimulate the Expansion of Regulatory T Cells while Concomitant Exposure to IL-12, CpG Oligodeoxynucleotides, and Anti-CD3/CD28 Promotes the Expansion of Activated Tumor Reactive Cells
J. Immunol.,
July 1, 2008;
181(1):
808 - 821.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Ninkovic and F.-G. Hanisch
O-Glycosylated Human MUC1 Repeats Are Processed In Vitro by Immunoproteasomes
J. Immunol.,
August 15, 2007;
179(4):
2380 - 2388.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Grube, S. Moritz, E. C. Obermann, K. Rezvani, A. Mackensen, R. Andreesen, and E. Holler
CD8+ T cells Reactive to Survivin Antigen in Patients with Multiple Myeloma
Clin. Cancer Res.,
February 1, 2007;
13(3):
1053 - 1060.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. M. Zirlik, D. Zahrieh, D. Neuberg, and J. G. Gribben
Cytotoxic T cells generated against heteroclitic peptides kill primary tumor cells independent of the binding affinity of the native tumor antigen peptide
Blood,
December 1, 2006;
108(12):
3865 - 3870.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Sommerfeldt, F. Schutz, C. Sohn, J. Forster, V. Schirrmacher, and P. Beckhove
The Shaping of a Polyvalent and Highly Individual T-Cell Repertoire in the Bone Marrow of Breast Cancer Patients
Cancer Res.,
August 15, 2006;
66(16):
8258 - 8265.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Sommerfeldt, P. Beckhove, Y. Ge, F. Schutz, C. Choi, M. Bucur, C. Domschke, C. Sohn, A. Schneeweis, J. Rom, et al.
Heparanase: a new metastasis-associated antigen recognized in breast cancer patients by spontaneously induced memory T lymphocytes.
Cancer Res.,
August 1, 2006;
66(15):
7716 - 7723.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Wierecky, M. R. Muller, S. Wirths, E. Halder-Oehler, D. Dorfel, S. M. Schmidt, M. Hantschel, W. Brugger, S. Schroder, M. S. Horger, et al.
Immunologic and Clinical Responses after Vaccinations with Peptide-Pulsed Dendritic Cells in Metastatic Renal Cancer Patients
Cancer Res.,
June 1, 2006;
66(11):
5910 - 5918.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C.-W. Liao, C.-A. Chen, C.-N. Lee, Y.-N. Su, M.-C. Chang, M.-H. Syu, C.-Y. Hsieh, and W.-F. Cheng
Fusion Protein Vaccine by Domains of Bacterial Exotoxin Linked with a Tumor Antigen Generates Potent Immunologic Responses and Antitumor Effects
Cancer Res.,
October 1, 2005;
65(19):
9089 - 9098.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Dorfel, S. Appel, F. Grunebach, M. M. Weck, M. R. Muller, A. Heine, and P. Brossart
Processing and presentation of HLA class I and II epitopes by dendritic cells after transfection with in vitro-transcribed MUC1 RNA
Blood,
April 15, 2005;
105(8):
3199 - 3205.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Appel, A. Rupf, M. M. Weck, O. Schoor, T. H. Brummendorf, T. Weinschenk, F. Grunebach, and P. Brossart
Effects of Imatinib on Monocyte-Derived Dendritic Cells Are Mediated by Inhibition of Nuclear Factor-{kappa}B and Akt Signaling Pathways
Clin. Cancer Res.,
March 1, 2005;
11(5):
1928 - 1940.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Choi, M. Witzens, M. Bucur, M. Feuerer, N. Sommerfeldt, A. Trojan, A. Ho, V. Schirrmacher, H. Goldschmidt, and P. Beckhove
Enrichment of functional CD8 memory T cells specific for MUC1 in bone marrow of patients with multiple myeloma
Blood,
March 1, 2005;
105(5):
2132 - 2134.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Y. Tsang, C. Palena, J. Yokokawa, P. M. Arlen, J. L. Gulley, G. P. Mazzara, L. Gritz, A. Gomez Yafal, S. Ogueta, P. Greenhalgh, et al.
Analyses of Recombinant Vaccinia and Fowlpox Vaccine Vectors Expressing Transgenes for Two Human Tumor Antigens and Three Human Costimulatory Molecules
Clin. Cancer Res.,
February 15, 2005;
11(4):
1597 - 1607.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Liu, B. Acres, J.-M. Balloul, N. Bizouarne, S. Paul, P. Slos, and P. Squiban
Gene-based vaccines and immunotherapeutics
PNAS,
October 5, 2004;
101(suppl_2):
14567 - 14571.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Narayanan, A. Jaramillo, N. D. Benshoff, L. G. Campbell, T. P. Fleming, J. R. Dietz, and T. Mohanakumar
Response of Established Human Breast Tumors to Vaccination with Mammaglobin-A cDNA
J Natl Cancer Inst,
September 15, 2004;
96(18):
1388 - 1396.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
U. Karsten, N. Serttas, H. Paulsen, A. Danielczyk, and S. Goletz
Binding patterns of DTR-specific antibodies reveal a glycosylation-conditioned tumor-specific epitope of the epithelial mucin (MUC1)
Glycobiology,
August 1, 2004;
14(8):
681 - 692.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Nencioni and P. Brossart
Cellular Immunotherapy with Dendritic Cells in Cancer: Current Status
Stem Cells,
July 1, 2004;
22(4):
501 - 513.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Wang, H. Chen, X. Jiang, M. Zhang, T. Wan, N. Li, X. Zhou, Y. Wu, F. Yang, Y. Yu, et al.
Identification of an HLA-A*0201-restricted CD8+ T-cell epitope SSp-1 of SARS-CoV spike protein
Blood,
July 1, 2004;
104(1):
200 - 206.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K.-Y. Tsang, C. Palena, J. Gulley, P. Arlen, and J. Schlom
A Human Cytotoxic T-Lymphocyte Epitope and Its Agonist Epitope from the Nonvariable Number of Tandem Repeat Sequence of MUC-1
Clin. Cancer Res.,
March 15, 2004;
10(6):
2139 - 2149.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. R. Muller, G. Tsakou, F. Grunebach, S. M. Schmidt, and P. Brossart
Induction of chronic lymphocytic leukemia (CLL)-specific CD4- and CD8-mediated T-cell responses using RNA-transfected dendritic cells
Blood,
March 1, 2004;
103(5):
1763 - 1769.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. M. Schmidt, K. Schag, M. R. Muller, T. Weinschenk, S. Appel, O. Schoor, M. M. Weck, F. Grunebach, L. Kanz, S. Stevanovic, et al.
Induction of Adipophilin-Specific Cytotoxic T Lymphocytes Using a Novel HLA-A2-Binding Peptide That Mediates Tumor Cell Lysis
Cancer Res.,
February 1, 2004;
64(3):
1164 - 1170.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Appel, A. M. Boehmler, F. Grunebach, M. R. Muller, A. Rupf, M. M. Weck, U. Hartmann, V. L. Reichardt, L. Kanz, T. H. Brummendorf, et al.
Imatinib mesylate affects the development and function of dendritic cells generated from CD34+ peripheral blood progenitor cells
Blood,
January 15, 2004;
103(2):
538 - 544.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Maecker, D. H. Sherr, R. H. Vonderheide, M. S. von Bergwelt-Baildon, N. Hirano, K. S. Anderson, Z. Xia, M. O. Butler, K. W. Wucherpfennig, C. O'Hara, et al.
The shared tumor-associated antigen cytochrome P450 1B1 is recognized by specific cytotoxic T cells
Blood,
November 1, 2003;
102(9):
3287 - 3294.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Rentzsch, S. Kayser, S. Stumm, I. Watermann, S. Walter, S. Stevanovic, D. Wallwiener, and B. Guckel
Evaluation of Pre-existent Immunity in Patients with Primary Breast Cancer: Molecular and Cellular Assays to Quantify Antigen-Specific T Lymphocytes in Peripheral Blood Mononuclear Cells
Clin. Cancer Res.,
October 1, 2003;
9(12):
4376 - 4386.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Casati, P. Dalerba, L. Rivoltini, G. Gallino, P. Deho, F. Rini, F. Belli, D. Mezzanzanica, A. Costa, S. Andreola, et al.
The Apoptosis Inhibitor Protein Survivin Induces Tumor-specific CD8+ and CD4+ T Cells in Colorectal Cancer Patients
Cancer Res.,
August 1, 2003;
63(15):
4507 - 4515.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. K. Ko, K. Kawano, J. L. Murray, M. L. Disis, C. L. Efferson, H. M. Kuerer, G. E. Peoples, and C. G. Ioannides
Clinical Studies of Vaccines Targeting Breast Cancer
Clin. Cancer Res.,
August 1, 2003;
9(9):
3222 - 3234.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. R. Muller, F. Grunebach, K. Kayser, W. Vogel, A. Nencioni, W. Brugger, L. Kanz, and P. Brossart
Expression of Her-2/neu on Acute Lymphoblastic Leukemias: Implications for the Development of Immunotherapeutic Approaches
Clin. Cancer Res.,
August 1, 2003;
9(9):
3448 - 3453.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. M. Schmidt, K. Schag, M. R. Muller, M. M. Weck, S. Appel, L. Kanz, F. Grunebach, and P. Brossart
Survivin is a shared tumor-associated antigen expressed in a broad variety of malignancies and recognized by specific cytotoxic T cells
Blood,
July 15, 2003;
102(2):
571 - 576.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. R. Muller, F. Grunebach, A. Nencioni, and P. Brossart
Transfection of Dendritic Cells with RNA Induces CD4- and CD8-Mediated T Cell Immunity Against Breast Carcinomas and Reveals the Immunodominance of Presented T Cell Epitopes
J. Immunol.,
June 15, 2003;
170(12):
5892 - 5896.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Milazzo, V. L. Reichardt, M. R. Muller, F. Grunebach, and P. Brossart
Induction of myeloma-specific cytotoxic T cells using dendritic cells transfected with tumor-derived RNA
Blood,
February 1, 2003;
101(3):
977 - 982.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Holtl, C. Zelle-Rieser, H. Gander, C. Papesh, R. Ramoner, G. Bartsch, H. Rogatsch, A. L. Barsoum, J. H. Coggin Jr., and M. Thurnher
Immunotherapy of Metastatic Renal Cell Carcinoma with Tumor Lysate-pulsed Autologous Dendritic Cells
Clin. Cancer Res.,
November 1, 2002;
8(11):
3369 - 3376.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Hernandez, F. Garcia-Pons, Y. C. Lone, H. Firat, J. D. Schmidt, P. Langlade-Demoyen, and M. Zanetti
Identification of a human telomerase reverse transcriptase peptide of low affinity for HLA A2.1 that induces cytotoxic T lymphocytes and mediates lysis of tumor cells
PNAS,
September 17, 2002;
99(19):
12275 - 12280.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Hebart, S. Daginik, S. Stevanovic, U. Grigoleit, A. Dobler, M. Baur, G. Rauser, C. Sinzger, G. Jahn, J. Loeffler, et al.
Sensitive detection of human cytomegalovirus peptide-specific cytotoxic T-lymphocyte responses by interferon-gamma -enzyme-linked immunospot assay and flow cytometry in healthy individuals and in patients after allogeneic stem cell transplantation
Blood,
May 15, 2002;
99(10):
3830 - 3837.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. S. von Bergwelt-Baildon, R. H. Vonderheide, B. Maecker, N. Hirano, K. S. Anderson, M. O. Butler, Z. Xia, W. Y. Zeng, K. W. Wucherpfennig, L. M. Nadler, et al.
Human primary and memory cytotoxic T lymphocyte responses are efficiently induced by means of CD40-activated B cells as antigen-presenting cells: potential for clinical application
Blood,
May 1, 2002;
99(9):
3319 - 3325.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. W. Mullins, T. N. J. Bullock, T. A. Colella, V. V. Robila, and V. H. Engelhard
Immune Responses to the HLA-A*0201-Restricted Epitopes of Tyrosinase and Glycoprotein 100 Enable Control of Melanoma Outgrowth in HLA-A*0201-Transgenic Mice
J. Immunol.,
November 1, 2001;
167(9):
4853 - 4860.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Schnurr, P. Galambos, C. Scholz, F. Then, M. Dauer, S. Endres, and A. Eigler
Tumor Cell Lysate-pulsed Human Dendritic Cells Induce a T-Cell Response against Pancreatic Carcinoma Cells: an in Vitro Model for the Assessment of Tumor Vaccines
Cancer Res.,
September 1, 2001;
61(17):
6445 - 6450.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Brossart, A. Schneider, P. Dill, T. Schammann, F. Grunebach, S. Wirths, L. Kanz, H.-J. Buhring, and W. Brugger
The Epithelial Tumor Antigen MUC1 Is Expressed in Hematological Malignancies and Is Recognized by MUC1-specific Cytotoxic T-Lymphocytes
Cancer Res.,
September 1, 2001;
61(18):
6846 - 6850.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Gorschluter, C. Ziske, A. Glasmacher, and I. G. H. Schmidt-Wolf
Current Clinical and Laboratory Strategies to Augment the Efficacy of Immunotherapy in Multiple Myeloma
Clin. Cancer Res.,
August 1, 2001;
7(8):
2195 - 2204.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Trojan, M. Witzens, J. L. Schultze, R. H. Vonderheide, S. Harig, A. M. Krackhardt, R. A. Stahel, and J. G. Gribben
Generation of Cytotoxic T Lymphocytes against Native and Altered Peptides of Human Leukocyte Antigen-A*0201 Restricted Epitopes from the Human Epithelial Cell Adhesion Molecule
Cancer Res.,
June 1, 2001;
61(12):
4761 - 4765.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. M. Soares, V. Mehta, and O. J. Finn
Three Different Vaccines Based on the 140-Amino Acid MUC1 Peptide with Seven Tandemly Repeated Tumor-Specific Epitopes Elicit Distinct Immune Effector Mechanisms in Wild-Type Versus MUC1-Transgenic Mice with Different Potential for Tumor Rejection
J. Immunol.,
June 1, 2001;
166(11):
6555 - 6563.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. M. Jaffee, R. H. Hruban, B. Biedrzycki, D. Laheru, K. Schepers, P. R. Sauter, M. Goemann, J. Coleman, L. Grochow, R. C. Donehower, et al.
Novel Allogeneic Granulocyte-Macrophage Colony-Stimulating Factor-Secreting Tumor Vaccine for Pancreatic Cancer: A Phase I Trial of Safety and Immune Activation
J. Clin. Oncol.,
January 1, 2001;
19(1):
145 - 156.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Brossart, S. Wirths, G. Stuhler, V. L. Reichardt, L. Kanz, and W. Brugger
Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells
Blood,
November 1, 2000;
96(9):
3102 - 3108.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Brossart, A. Zobywalski, F. Grünebach, L. Behnke, G. Stuhler, V. L. Reichardt, L. Kanz, and W. Brugger
Tumor Necrosis Factor {{alpha}} and CD40 Ligand Antagonize the Inhibitory Effects of Interleukin 10 on T-Cell Stimulatory Capacity of Dendritic Cells
Cancer Res.,
August 1, 2000;
60(16):
4485 - 4492.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
J. Gong, N. Nikrui, D. Chen, S. Koido, Z. Wu, Y. Tanaka, S. Cannistra, D. Avigan, and D. Kufe
Fusions of Human Ovarian Carcinoma Cells with Autologous or Allogeneic Dendritic Cells Induce Antitumor Immunity
J. Immunol.,
August 1, 2000;
165(3):
1705 - 1711.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. H. Andersen, L. O. Pedersen, J. C. Becker, and P. t. Straten
Identification of a Cytotoxic T Lymphocyte Response to the Apoptosis Inhibitor Protein Survivin in Cancer Patients
Cancer Res.,
February 1, 2000;
61(3):
869 - 872.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
P. Brossart, B. Spahlinger, F. Grunebach, G. Stuhler, V. L. Reichardt, L. Kanz, W. Brugger;, T. Mutis, and E. Goulmy
Induction of Minor Histocompatibility Antigen HA-1-Specific Cytotoxic T Cells for the Treatment of Leukemia After Allogeneic Stem Cell Transplantation
Blood,
December 15, 1999;
94(12):
4374 - 4376.
[Full Text]
[PDF]
|
|
|
|
|
